Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Neurogen Begins Phase I Trial for Obesity Drug | Contract Pharma

What are you searching for?

Sign in

Neurogen Begins Phase I Trial for Obesity Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Neurogen Corp. has begun a Phase I trial for its leading drug candidate for treatment of obesity. The compound, NGD-4715, works as an antagonist at the melanin concentrating hormone receptor-1 (MCH1).

William H. Koster, president and chief executive officer, said, “We are extremely pleased to be entering human testing exploring this promising new target. While the MCH1 mechanism has been a target of high interest in the pharmaceutical community, we believe most in the industry have encountered significant obstacles to advancing drug candidates into human studies. Neurogen has established a leading position in this promising new arena and we hope to provide an effective therapeutic for the growing number of patients affected by obesity and its many co-morbidities, including diabetes and hypertension.”

The Phase I trial is a randomized, double-blind, placebo-controlled evaluation in healthy overweight and obese subjects of the safety, pharmacokinetics, and pharmacodynamics of single rising oral doses of NGD-4715. The study will include 84 male and female subjects. This study will be conducted in the U.S. and standard safety assessments will be made.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters